RenovoRx, Inc., a life sciences company specializing in targeted oncology therapies, has announced the launch of the PanTheR Post-Marketing Registry Study. This multi-center, observational study aims to evaluate the long-term safety and survival outcomes of patients with solid tumors treated using the RenovoCath device for targeted drug delivery. The study will collect real-world data across diverse cancer types and clinical environments, providing insights into the device's safety and effectiveness in a real-world setting. Patient enrollment is expected to commence before the end of September 2025. The study's results have not yet been presented and will provide valuable data to inform future clinical trial designs and treatment strategies. Each participating cancer center will purchase RenovoCath devices for use in the study from RenovoRx.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。